Atossa Therapeutics President and CEO Dr. Steven C. Quay Issues Annual Letter to Stockholders Highlighting Key Recent Accomplishments and Strategy for 2022
SEATTLE, Jan. 27, 2022 -- Atossa Therapeutics, Inc. , a clinical stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet medical need in oncology and...
United States Karolinska Institutet Kyle Guse Head Of The Department Medical Epidemiology Company Contact Avance Clinical Pty Ltd
Source: marketscreener.com